In December 2014 PLoS ONE published online this new medical article, “Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma” (free FULL text).
This article presents research about diagnostic markers for malignant pleural mesothelioma (MPM), starting with the premise that there is no established single diagnostic marker for pleural mesothelioma (the most common type of “meso”).
From the final part of the Abstract for this new medical journal article:
Moreover, [dipeptidyl peptidase IV (DPPIV)] enzyme activity in the pleural fluid of patients with MPM with an epithelioid subtype were significantly increased compared with those in the [other benign pleural diseases (OPD)] cohort (P = 0.009). Patients with MPM who had lower specific DPPIV activity, determined as DPPIV/sCD26, showed significantly prolonged survival compared with those with higher specific DPPIV activity (P = 0.028). Serum [soluble CD26 (sCD26)] and DPPIV enzyme activity appear to be useful biomarkers for differentiating patients with MPM from [subjects with past asbestos exposure (SPE)]. The sCD26 levels or DPPIV enzyme activity in pleural fluid appear to be biomarkers in patients with an epithelioid subtype of MPM. DPPIV activity in serum or pleural fluid appears to be predictive for the prognosis of patients with MPM.
We will continue to monitor the medical literature for mesothelioma research and report significant developments here.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.